In this context, TGF-β signal pathway mutations and/or alterations mutations to TGF-β cascade components have been associated with several bone disorders and many carcinomas [58, 59].Several high-throughput genomic and transcriptomic studies have delineated the intra-tumoral heterogeneity of OS [11, 60–62]. This evidence concerns the gene TGFB1 and carcinoma.